SCHEMBL2086819

SCHEMBL2086819

CON(C)C(=O)c1cn2c(C)cccc2n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.59
RAB9A P51151 6/20 0.42
NPC1 O15118 3/20 0.42
TP53 P04637 1/20 0.39
MAPT P10636 4/20 0.37
KDM4E B2RXH2 3/20 0.37
HRH3 Q9Y5N1 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
TDP1 Q9NUW8 2/20 0.36
LMNA P02545 1/20 0.36
RECQL P46063 1/20 0.36
BLM P54132 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CLK1 P49759 1/20 0.35
DYRK1A Q13627 1/20 0.35
DYRK1B Q9Y463 1/20 0.35
TRPM8 Q7Z2W7 2/20 0.34
PDE4B Q07343 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30178097 0.85 GAA (0.61) GAARAB9ANPC1TP53MAPT
SCHEMBL2086824 0.78 GAA (0.36) GAARAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL119926 0.77 GAA (0.66) GAARAB9ANPC1TP53MAPT
SCHEMBL10242648 0.77 GAA (0.66) GAARAB9ANPC1TP53MAPT
SCHEMBL3282406 0.76 GAA (0.64) GAARAB9ANPC1TP53MAPT
SCHEMBL15902217 0.76 RBP4 (0.39) GAARAB9ANPC1KDM4EKMT2A
SCHEMBL29870964 0.76 PTGS1 (0.59) RAB9ANPC1TP53MAPTKDM4E
SCHEMBL3769993 0.74 APP (0.44) RAB9ANPC1TP53MAPTKDM4E
SCHEMBL101291 0.74 GAA (1.00) GAARAB9ANPC1MAPTKDM4E
SCHEMBL8374791 0.73 KDM4E (0.45) GAARAB9ANPC1TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902219-B2 2-benzoylimidazopyridine derivatives, preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2011-03-08 US disclosed
US-20100317688-A1 2-HETEROAROYLIMIDAZOL[1,2-a]PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-12-16 US disclosed
US-20090143420-A1 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317688-A1 2-HETEROAROYLIMIDAZOL[1,2-a]PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF XDH, CYP11B2, IL4I1 GAA 921/4885RAB9A 1356/4885NPC1 1659/4885
US-20090143420-A1 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF NR4A2, NR4A3, NCOR1 GAA 4741/4885RAB9A 3310/4885NPC1 791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.